SCHEMBL8158261

SCHEMBL8158261

C=CCOC(=O)C(CCc1ccc(CC(=O)OC)cc1)(Cc1ccc(CC(=O)OC)cc1)C(=O)OCC=C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.48
CYP4A11 Q02928 1/20 0.48
PTPRB P23467 5/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
PTPN1 P18031 3/20 0.38
ACP1 P24666 2/20 0.38
PTPRC P08575 1/20 0.38
PTPN2 P17706 1/20 0.38
PTPRG P23470 1/20 0.38
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
TP53 P04637 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 2/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 3/20 0.35
GAA P10253 1/20 0.35
GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2490598 0.86 PTPRB (0.46) CYP4F2CYP4A11PTPRBSMN1; SMN2MAPT
SCHEMBL8245053 0.81 PTPRB (0.41) CYP4F2CYP4A11PTPRBSMN1; SMN2MAPT
SCHEMBL2160851 0.80 CYP4A11 (0.48) CYP4F2CYP4A11PTPRBSMN1; SMN2MAPT
SCHEMBL2294364 0.79 PTPRB (0.40) CYP4F2CYP4A11PTPRBSMN1; SMN2MAPT
SCHEMBL2289320 0.79 PTPRB (0.40) CYP4F2CYP4A11PTPRBSMN1; SMN2MAPT
SCHEMBL8240660 0.78 CYP4F2 (0.34) CYP4F2CYP4A11PTPRBSMN1; SMN2LMNA
SCHEMBL8240083 0.74 PTPRB (0.37) CYP4F2CYP4A11PTPRBSMN1; SMN2MAPT
SCHEMBL29100373 0.72 CYP3A4 (0.50) PTPRBSMN1; SMN2PTPN1PTPRCPTPN2
SCHEMBL24341135 0.72 SMN1; SMN2 (0.52) CYP4F2CYP4A11SMN1; SMN2LMNAMAPT
SCHEMBL10085448 0.72 CYP4F2 (0.46) CYP4F2CYP4A11PTPRBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217063-B2 Lactam-substituted dicarboxylic acids and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-07-10 US disclosed
EP-2142504-B1 LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF Bayer Pharma AG (DE) 2011-10-26 EP disclosed
US-20100197680-A1 LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2010-08-05 US disclosed
WO-2008119457-A2 LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197680-A1 LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF DDO, DDC, BCAT2 CYP4F2 672/4885CYP4A11 2160/4885PTPRB 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.